Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Diabetes & Metabolism

• Publication date

  2003-06-01

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1016/S1262-3636(07)70030-7PMID 12909809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry

  2005cited by this paper
• Is metformin cardioprotective?

  2003cited by this paper
• Loss of Preconditioning by Attenuated Activation of Myocardial ATP-Sensitive Potassium Channels in Elderly Patients Undergoing Coronary Angioplasty

  2002cited by this paper
• Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

  2002cited by this paper
• Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

  2002cited by this paper
• Post-stenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic drug glibenclamide in patients with coronary artery disease

  2002cited by this paper
• Oral hypoglycemic sulfonylurea glimepiride preserves the myoprotective effects of ischemic preconditioning.

  2002cited by this paper
• Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients

  2002cited by this paper
• Cardiovascular Safety of Oral Antidiabetic Agents: The Insulin Secretagogues

  2002cited by this paper
• Role of sarcolemmal KATP channels in cardioprotection against ischemia/reperfusion injury in mice

  2002cited by this paper
• Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits.

  2002cited by this paper
• Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes.

  2002cited by this paper
• Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice.

  2002cited by this paper
• Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.

  2001cited by this paper
• Glibenclamide effects on reperfusion-induced malignant arrhythmias and left ventricular mechanical recovery from stunning in conscious sheep.

  2001cited by this paper
• Glimepiride block of cloned β‐cell, cardiac and smooth muscle KATP channels

  2001cited by this paper
• Evidence-Based Diabetes Care

  2001cited by this paper
• Effects of Nicorandil Administration on Survival Rate and Arrhythmias during Reperfusion in Anesthetized Rabbits

  2001cited by this paper
• Lack of antagonism between nicorandil and sulfonylurea in stable angina pectoris.

  2001cited by this paper
• Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone.

  2001cited by this paper
• Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease – preterax and diamicron MR controlled evaluation

  2001cited by this paper
• Effects of sulfonylurea derivatives on ischemia-induced loss of function in the isolated rat heart.

  2001cited by this paper
• Oral antidiabetic treatment in patients with coronary disease: Time‐related increased mortality on combined glyburide/metformin therapy over a 7.7‐year follow‐up

  2001cited by this paper
• Glimepiride, a Novel Sulfonylurea, Does Not Abolish Myocardial Protection Afforded by Either Ischemic Preconditioning or Diazoxide

  2001cited by this paper
• Sulfonylureas Are Not Associated With Increased Mortality in Diabetics Treated With Thrombolysis for Acute Myocardial Infarction

  2001influential reference
• Study rationale and design of ADVANCE: Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation

  2001cited by this paper
• Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels.

  2001cited by this paper
• Structural basis for the interference between nicorandil and sulfonylurea action.

  2001cited by this paper
• The sulfonylurea glimepiride does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide

  2000cited by this paper
• Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview.

  2000cited by this paper
• Randomized controlled trials remain fundamental to clinical decision making in Type II diabetes mellitus: a comment to the debate on randomized controlled trials (For debate) [corrected].

  2000cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study

  2000cited by this paper
• Randomized controlled trials remain fundamental to clinical decision making in Type II diabetes mellitus: a comment to the debate on randomized controlled trials

  2000cited by this paper
• Effects of glibenclamide, a k atp channel blocker, on warm‐up phenomenon in type 11 diabetic patients with chronic stable angina pectoris

  2000cited by this paper
• Therapy of type 2 diabetes, cardiovascular death, and the UGDP.

  1999cited by this paper
• Comparative aspects of the function and mechanism of SUR1 and MDR1 proteins.

  1999cited by this paper
• Effects of K(ATP) channel blockade by glibenclamide on the warm-up phenomenon.

  1999influential reference
• Differential sensitivity of beta-cell and extrapancreatic KATP channels to gliclazide

  1999cited by this paper
• Diabetes and coronary artery disease: time to stop taking the tablets

  1999cited by this paper
• Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.

  1999influential reference
• Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction.

  1999influential reference
• Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.

  1999influential reference
• Sulfonylureas and mortality in diabetic patients after myocardial infarction.

  1998cited by this paper
• Arrhythmias and Mortality After Myocardial Infarction in Diabetic Patients: Relationship to diabetes treatment

  1998cited by this paper
• Attenuation of myocardial ischemia with repeated exercise in subjects with chronic stable angina: relation to myocardial contractility, intensity of exercise and the adenosine triphosphate-sensitive potassium channel.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease

  1998cited by this paper
• Diabetes and coronary artery disease: time to stop taking the tablets?

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Glibenclamide does not prevent action potential shortening induced by ischemia in anesthetized rabbits but reduces ischemia-induced arrhythmias.

  1998cited by this paper
• Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.

  1998cited by this paper
• Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients.

  1997cited by this paper
• Case-control study of sudden infant death syndrome in Scotland, 1992-5

  1997cited by this paper
• Effects of tolbutamide on ATP-sensitive K+ channels from human right atrial cardiac myocytes.

  1997cited by this paper
• Blockade of K(ATP) channels with glibenclamide does not abolish preconditioning during demand ischemia.

  1997cited by this paper
• Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease

  1997cited by this paper
• Concerning the effect of the K+ channel blocking agent glibenclamide on ischaemic and reperfusion arrhythmias.

  1997cited by this paper
• Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited.

  1997cited by this paper
• KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats.

  1997cited by this paper
• Cardiovascular Effects of Conventional Sulfonylureas and Glimepiride

  1996cited by this paper
• A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels.

  1996cited by this paper
• Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans

  1996influential reference
• Effects of tolbutamide on vascular ATP-sensitive potassium channels in humans. Comparison with literature data on glibenclamide and glimepiride.

  1996cited by this paper
• Blockade of vascular ATP-sensitive potassium channels reduces the vasodilator response to ischaemia in humans

  1996cited by this paper
• Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?

  1996cited by this paper
• Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM?

  1995cited by this paper
• ATP gated potassium channels in acute myocardial hibernation and reperfusion.

  1994cited by this paper
• Ischemic Preconditioning During Coronary Angioplast Is Prevented by Glibenclamide, a Selective ATP‐Sensitive K+ Channel Blocker

  1994cited by this paper
• Effects of glibenclamide on ventricular fibrillation in non‐insulin-dependent diabetics with acute myocardial infarction

  1994cited by this paper
• Chronic gliclazide treatment affects basal and post-ischemic cardiac function in diabetic rats.

  1994cited by this paper
• Glibenclamide-induced oscillation of canine coronary artery is independent of myocardial ischemia.

  1994cited by this paper
• Effect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia.

  1994cited by this paper
• Ketamine-xylazine anaesthesia permits a KATP channel antagonist to attenuate preconditioning in rabbit myocardium.

  1994cited by this paper
• Cardioprotective actions of potassium channel openers.

  1994cited by this paper
• Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine.

  1994cited by this paper
• The ATP-sensitive potassium channel blocker glibenclamide (glyburide) does not abolish preconditioning in isolated ischemic rat hearts.

  1993cited by this paper
• EFFECT OF NICORANDIL ON POST‐ISCHAEMIC CONTRACTILE DYSFUNCTION IN THE HEART: ROLES OF ITS ATP‐SENSITIVE K’ CHANNEL OPENING PROPERTY AND NITRATE PROPERTY

  1993cited by this paper
• Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs.

  1993cited by this paper
• An explanation for the reported observation that ATP dependent potassium channel openers mimic preconditioning.

  1993cited by this paper
• Ischemic cardioprotection by ATP-sensitive K+ channels involves high-energy phosphate preservation.

  1993cited by this paper
• The protection by ischemic preconditioning against myocardial ischemia- and reperfusion‐induced arrhythmias is not mediated by ATP‐sensitive potassium channels in rats

  1993cited by this paper
• Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide.

  1993influential reference
• Are ATP sensitive potassium channels involved in the pronounced antiarrhythmic effects of preconditioning?

  1993cited by this paper
• The Effects of the ATP‐Dependent Potassium Channel Antagonist, Glyburide, on Coronary Blood Flow and Susceptibility to Ventricular Fibrillation in Unanesthetized Dogs

  1993cited by this paper
• Actions of Pinacidil at a Reduced Potassium Concentration: A Direct Cardiac Effect Possibly Involving the ATP‐Dependent Potassium Channel

  1993cited by this paper
• Role of ATP‐Sensitive K+ Channel on ECG ST Segment Elevation During a Bout of Myocardial Ischemia A Study on Epicardial Mapping in Dogs

  1993cited by this paper
• Sulphonylurea drugs no longer inhibit ATP-sensitive K+ channels during metabolic stress in cardiac muscle.

  1993cited by this paper
• Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbit hearts.

  1993cited by this paper
• Glibenclamide does not abolish the protective effect of preconditioning on stunning in the isolated perfused rat heart.

  1993cited by this paper
• Effect of blockade of the ATP-sensitive potassium channel on metabolic coronary vasodilation in the dog.

  1993cited by this paper
• Effects of potassium channel modulation during global ischaemia in isolated rat heart with and without cardioplegia.

  1992cited by this paper
• Glibenclamide decreases basal coronary blood flow in anesthetized dogs.

  1992cited by this paper
• Nicorandil Attenuates Myocardial Dysfunction Associated with Transient Ischemia by Opening ATP-Dependent Potassium Channels

  1992cited by this paper
• Effects of intracoronary cromakalim on postischaemic contractile function and action potential duration.

  1992cited by this paper
• Pro-arrhythmic effect of nicorandil in isolated rabbit atria and its suppression by tolbutamide and quinidine.

  1992cited by this paper
• Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.

  1992cited by this paper
• Effects of glibenclamide on ventricular arrhythmias and cardiac function in ischaemia and reperfusion in isolated rat heart.

  1992cited by this paper
• ATP-sensitive potassium channel is essential to maintain basal coronary vascular tone in vivo.

  1992cited by this paper
• Effects of glibenclamide and nicorandil on cardiac function during ischemia and reperfusion in isolated perfused rat hearts.

  1991cited by this paper

• Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population‐based cohort study

  2023cites this paper
• Evaluating gliclazide for the treatment of type 2 diabetes mellitus

  2022cites this paper
• The role of sulfonylureas in the treatment of type 2 diabetes

  2021cites this paper
• Sulphonylureas in the management of type 2 diabetes: To be or not to be?

  2021cites this paper
• The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy

  2020cites this paper
• Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia

  2018cites this paper
• Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm”

  2018cites this paper
• Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events

  2017cites this paper
• The Effect of Cardiovascular Risk Factors on the Coronary Circulation

  2017cites this paper
• Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.

  2017cites this paper
• chorego – stanowisko American Diabetes Association ( ADA ) i European Association for the Study of Diabetes ( EASD )

  2016cites this paper
• Dose‐response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes

  2016cites this paper
• Diabetes Management and Cardiovascular Risk: Are SGLT-2 Inhibitors the Safest?

  2016cites this paper
• Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer

  2015cites this paper
• Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies

  2015cites this paper
• Exploring the Distribution of Prescription for Sulfonylureas in Patients with Type 2 Diabetes According to Cardiovascular Risk Factors Within a Canadian Primary Care Setting.

  2015cites this paper
• Cardiorenal Syndromes: Advances in Determining Diagnosis, Prognosis and Therapy

  2015cites this paper
• Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.

  2015cites this paper
• The Importance of the Treatment Strategy Changes in the Long-Term Evolution of Type 2 Diabetic Patients with Sub-Optimal Glycaemic Control After Acute Coronary Syndrome

  2015cites this paper
• FORMACIÓN CONTINUADA. ACTUALIZACIÓN EN MEDICINA DE FAMILIA Seguridad cardiovascular de los antidiabéticos no insulínicos. Posicionamiento científico SEMERGEN

  2014cites this paper
• Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case–control study

  2014cites this paper
• Optimal therapy of type 2 diabetes: a controversial challenge

  2014cites this paper
• Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.

  2013cites this paper
• Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease

  2013cites this paper
• Glibenclamide: proven facts, perspectives, discussions

  2013cites this paper
• [Oral antidiabetic drugs. How to begin and combine without cardiovascular risk].

  2013cites this paper
• Antidiabéticos orais. Como começar e combinar sem risco cardiovascular

  2013cites this paper
• The clinical application of glibenclamide: the problem of safety and efficacy

  2012cites this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cites this paper
• Variations in tissue selectivity amongst insulin secretagogues: a systematic review

  2012cites this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cites this paper
• The effect of the introduction of a standard monitoring protocol on the investigations performed on the metabolic control of type 2 diabetes at Addington Hospital Medical Outpatients Department, Durban, South Africa

  2012cites this paper
• Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction--a nationwide study.

  2011cites this paper
• Effects of glucose-lowering drugs in patients with diabetes and myocardial infarction

  2011cites this paper
• The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury

  2011cites this paper
• Stratégies de mise en œuvre des hypoglycémiants et risque cardiovasculaire

  2010cites this paper
• Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction.

  2010cites this paper
• Outcomes in Diabetic Patients with Acute Myocardial Infarction Impact of Type of Preadmission Sulfonylureas on Mortality and Cardiovascular

  2010cites this paper
• Myocardial infarction and diabetes mellitus Studies on glucose lowering therapies and novel risk markers based on observations from the DIGAMI 2 trial

  2010cites this paper
• Glimepiride treatment upon reperfusion limits infarct size via the phosphatidylinositol 3-kinase/Akt pathway in rabbit hearts.

  2009cites this paper
• Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.

  2009cites this paper
• Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population‐based follow‐up study

  2009cites this paper
• Insulin-secretagogue activity of p-methoxycinnamic acid in rats, perfused rat pancreas and pancreatic beta-cell line.

  2008cites this paper
• Oral Glyburide, But Not Glimepiride, Blocks the Infarct-Size Limiting Effects of Pioglitazone

  2008cites this paper
• Therapie des Diabetes mellitus Typ 2 und kardiovaskuläre Komplikationen

  2008cites this paper
• Metabolic Syndrome and Insulin Resistance: Perioperative Considerations

  2008cites this paper
• Sulfonilureas en el tratamiento del paciente con diabetes mellitus tipo 2

  2008cites this paper
• Optimizing combination treatment in the management of type 2 diabetes

  2007cites this paper
• The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

  2007cites this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cites this paper
• Sicherheitsaspekte oraler Antidiabetika

  2007cites this paper
• Does early insulin treatment decrease the risk of microangiopathy in non-obese adults with diabetes?

  2007cites this paper
• A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes

  2007cites this paper
• Diabete sucre et decompensation cardiaque: specificites ethiopathogeniques et therapeutiques.

  2006cites this paper
• Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

  2006cites this paper
• Diabetes mellitus and anesthesia.

  2006cites this paper
• Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus

  2006cites this paper
• Sulfonylureas and the risk of myocardial infarction.

  2006cites this paper
• Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents

  2006cites this paper
• Diabète sucré et décompensation cardiaque: spécificités éthiopathogéniques et thérapeutiques

  2006cites this paper
• Review: Sulphonylureas and cardiovascular risk: facts and controversies

  2006cites this paper
• Sulphonylureas and cardiovascular risk: facts and controversies

  2006cites this paper
• Coronary artery disease in women: a review on prevention, pathophysiology, diagnosis, and treatment

  2006cites this paper
• Drug Class Review on Oral Hypoglycemics

  2005cites this paper
• Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.

  2005cites this paper
• Drug Interactions of Clinical Importance with Antihyperglycaemic Agents

  2005cites this paper
• ATP-sensitive potassium channels.

  2005cites this paper
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  2005cites this paper
• Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway.

  2005cites this paper
• Relationship between antidiabetic treatment with QT dispersion during acute coronary syndromes in type 2 diabetes: comparison between patients receiving sulfonylureas and insulin.

  2005cites this paper
• 42 - Insulin, glucagon, and oral hypoglycemic drugs

  2005cites this paper